MCID: PRS045
MIFTS: 55

Prostatic Hypertrophy

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 72
Benign Prostatic Hypertrophy 72
Prostatic Hyperplasia 72

Classifications:



External Ids:

Disease Ontology 12 DOID:11132
UMLS 72 C0005001 C1739363 C2937421

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatic hyperplasia, benign and prostate disease, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Scopolamine and Finasteride have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and smooth muscle, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 31.5 KLK3 AR ADRA1A
2 prostate disease 30.9 KLK3 CYP19A1 AR
3 gynecomastia 29.2 PGR KLK3 ESR1 CYP19A1 AR
4 prostate cancer 28.9 KLK3 ESR1 EGFR EGF CYP19A1 AR
5 prostatic adenoma 10.7
6 male reproductive organ benign neoplasm 10.5 KLK3 CYP19A1
7 bartholin's gland adenoma 10.5 PGR ESR1
8 vestibular gland benign neoplasm 10.5 PGR ESR1
9 lung leiomyoma 10.5 PGR ESR1
10 vulvar syringoma 10.5 PGR ESR1
11 postmenopausal atrophic vaginitis 10.5 ESR1 AR
12 glassy cell carcinoma of the cervix 10.5 PGR ESR1
13 vaginitis 10.5 ESR1 AR
14 nodular prostate 10.5 KLK3 AR
15 vulvar leiomyoma 10.5 PGR ESR1
16 trigonitis 10.5 PGR ESR1
17 vulvar benign neoplasm 10.5 PGR ESR1
18 predominantly cortical thymoma 10.5 PGR ESR1
19 breast medullary carcinoma 10.5 PGR ESR1
20 androgen insensitivity, partial 10.5 CYP19A1 AR
21 bartholin's gland benign neoplasm 10.5 PGR ESR1
22 cribriform carcinoma 10.5 PGR ESR1
23 progesterone resistance 10.5 PGR ESR1
24 adenoid basal cell carcinoma 10.5 PGR ESR1
25 endometrial mucinous adenocarcinoma 10.5 PGR ESR1
26 adenoma 10.5
27 transsexualism 10.5 CYP19A1 AR
28 benign metastasizing leiomyoma 10.5 PGR CYP19A1
29 synchronous bilateral breast carcinoma 10.5 PGR ESR1
30 deep angioma 10.4 PGR ESR1
31 sebaceous adenoma 10.4 ESR1 EGF
32 alopecia, androgenetic, 1 10.4 CYP19A1 AR
33 cervical carcinosarcoma 10.4 PGR ESR1
34 female reproductive endometrioid cancer 10.4 PGR ESR1
35 acute cystitis 10.4
36 glycogen-rich clear cell breast carcinoma 10.4 PGR ESR1
37 intramuscular hemangioma 10.4 PGR ESR1
38 endometrial disease 10.4 ESR1 CYP19A1
39 cervical clear cell adenocarcinoma 10.4 PGR ESR1
40 retinitis pigmentosa 47 10.4 PGR ESR1
41 bartholin's gland disease 10.4 PGR AR
42 corneal abscess 10.4 PGR AR
43 adenosarcoma 10.4 PGR ESR1
44 calcifying aponeurotic fibroma 10.4 PGR EGF
45 retinitis pigmentosa 20 10.3 PGR ESR1
46 uterine corpus cancer 10.3 PGR ESR1
47 endometrial stromal nodule 10.3 PGR CYP19A1
48 impotence 10.3
49 breast cyst 10.3 KLK3 EGF
50 papillary hidradenoma 10.3 PGR AR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show all 49)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Kidney Disease
Left Bundle Branch Hemiblock Lipoma of Spermatic Cord
Low Compliance Bladder Nephrolithiasis, X-Linked Recessive, with Renal Failure
Neurogenic Bladder Parkinson Disease, Late-Onset
Pelvic Varices Penile Disease
Peyronie's Disease Pinta Disease
Pneumoconiosis Postinflammatory Pulmonary Fibrosis
Prostate Calculus Prostate Cancer
Prostate Carcinoma in Situ Prostate Disease
Prostatitis Prostatocystitis
Renal Pelvis Carcinoma Right Bundle Branch Block
Silicosis Spermatocele
Ureter, Cancer of Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction Varicocele
Vesicoureteral Reflux 1

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ADRA1A ADRA1D AR CD36 CYP19A1 ESR1
2 cardiovascular system MP:0005385 10.01 ADRA1A ADRA1D AR CD36 CYP19A1 EGFR
3 endocrine/exocrine gland MP:0005379 9.87 AR CD36 CYP19A1 EGF EGFR ESR1
4 immune system MP:0005387 9.86 AR CD36 CYP19A1 EGF EGFR ESR1
5 adipose tissue MP:0005375 9.85 AR CD36 CYP19A1 EGFR ESR1
6 digestive/alimentary MP:0005381 9.85 AR CD36 CYP19A1 EGF EGFR ESR1
7 integument MP:0010771 9.63 AR CYP19A1 EGF EGFR ESR1 PGR
8 muscle MP:0005369 9.56 ADRA1A ADRA1D AR CD36 CYP19A1 EGFR
9 renal/urinary system MP:0005367 9.1 ADRA1A AR CD36 CYP19A1 EGFR ESR1

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
2
Finasteride Approved Phase 4 98319-26-7 57363
3
Silodosin Approved Phase 4 160970-54-7
4
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
5
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
6
Methyltestosterone Approved Phase 4 58-18-4 6010
7
Testosterone enanthate Approved Phase 4 315-37-7 9416
8
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Saw palmetto Approved, Experimental, Investigational Phase 4
11
Sodium citrate Approved, Investigational Phase 4 68-04-2
12
carbamide peroxide Approved Phase 4 124-43-6
13
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
14
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
15
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
16
Tranexamic Acid Approved Phase 4 1197-18-8 5526
17
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
20
Mirabegron Approved Phase 4 223673-61-8 9865528
21
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
22
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Cimetropium Experimental, Investigational Phase 4 150521-16-7
27 Naftopidil Investigational Phase 4 57149-07-2
28
Fibrinolysin Investigational Phase 4 9004-09-5
29 Cola Phase 4
30 Anticonvulsants Phase 4
31 Bromides Phase 4
32 Adjuvants, Anesthesia Phase 4
33 Antiemetics Phase 4
34 Gastrointestinal Agents Phase 4
35 Mydriatics Phase 4
36 Butylscopolammonium Bromide Phase 4
37 Anti-Infective Agents Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Mitogens Phase 4
41 Anesthetics, Local Phase 4
42 Parasympatholytics Phase 4
43 Solifenacin succinate Phase 4 242478-38-2
44 Muscarinic Antagonists Phase 4
45 Cholinergic Antagonists Phase 4
46 Anabolic Agents Phase 4
47 Antineoplastic Agents, Hormonal Phase 4
48 Testosterone 17 beta-cypionate Phase 4
49 Saw palmetto extract Phase 4
50 Platelet Aggregation Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 558)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
3 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
4 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4 Alfuzosin;Tamsulosin
5 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
6 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
7 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
8 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
9 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
10 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
11 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
12 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
13 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
14 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
15 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
16 Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study" Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
17 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
18 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
19 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
20 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
21 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
22 Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study Completed NCT01260129 Phase 4 Silodosin;Silodosin
23 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Completed NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
24 Dutasteride Treatment for the Reduction of Heavy Drinking Completed NCT01758523 Phase 4 Dutasteride;sugar pill
25 Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
26 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
27 Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance Completed NCT00108420 Phase 4 Prazosin
28 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
29 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
30 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
31 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
32 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
33 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
34 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
35 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
36 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
37 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
38 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
39 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
40 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
41 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
42 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
43 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
44 An Open, Non-Comparative, Multicenter Study on the Sexual Function Improvement Following Treatment With Alfuzosin in Patients With Benign Prostate Hyperplasia Completed NCT00427882 Phase 4 ALFUZOSIN
45 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
46 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
47 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
48 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
49 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
50 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alfuzosin
Doxazosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

41
Prostate, Testes, Smooth Muscle, Bone, Endothelial, Kidney, Heart

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 15954)
# Title Authors PMID Year
1
Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia. 38
30724641 2019
2
Identification of key genes and pathways in benign prostatic hyperplasia. 38
31187492 2019
3
Characterization and screening of cyclooxygenase-2 inhibitors from Zi-shen pill by affinity ultrafiltration-ultra performance liquid chromatography mass spectrometry. 38
31029761 2019
4
Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia. 38
31145504 2019
5
Effects of dexamethasone on postoperative urinary retention after laparoscopic inguinal hernia repair. 38
30406386 2019
6
Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies. 38
31039100 2019
7
Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis. 38
30701625 2019
8
Multimodality approach to imaging giant multilocular cystadenoma of the prostate: A rare entity. 38
31338138 2019
9
Re: Second-Generation of Temporary Implantable Nitinol Device for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Prospective, Multicentre Study at 1 Year of Follow-up. 38
31219387 2019
10
Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia. 38
30450921 2019
11
Oxidative stress before and after surgery in benign prostatic hyperplasia patients. 38
31158928 2019
12
It's Time to Take Advantage of Robotic Assisted Simple Prostatectomy in Large Benign Prostatic Hyperplasia. 38
30588785 2019
13
The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. 38
30644234 2019
14
NICE Guidance - Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. 38
31436038 2019
15
Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. 38
31059668 2019
16
Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data. 38
29383563 2019
17
Protein Cytl1: its role in chondrogenesis, cartilage homeostasis, and disease. 38
31089746 2019
18
Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. 38
31264168 2019
19
Suppressor of activator protein-1 regulated by interferon expression in prostate cancer tissues and cells. 38
31276688 2019
20
Re: Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications. 38
31219374 2019
21
Data on somatic mutations obtained by whole exome sequencing of FFPE tissue samples from Russian patients with prostate cancer. 38
31223638 2019
22
Efficacy of the VIRTUE male quadratic sling in the treatment of stress urinary incontinence: A retrospective study. 38
31387835 2019
23
Therapeutic efficacy of orally administered pollen for nonallergic diseases: An umbrella review. 38
31435975 2019
24
Incontinence after Prostate Treatment: AUA/SUFU Guideline. 38
31059663 2019
25
Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study. 38
31189024 2019
26
Patient-reported Goal Achievement after Treating Male Benign Prostatic Hyperplasia with Alpha-adrenergic Antagonist: A 12-week Prospective Multicenter Study. 38
30345500 2019
27
Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model. 38
31429633 2019
28
Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004-2013: The Urologic Diseases in America Project. 38
31430232 2019
29
Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. 38
30734990 2019
30
[A comparative study of prostatic artery embolization in the treatment of benign prostatic hyperplasia with different prostatic volume]. 38
31434423 2019
31
Re: Oxidative Damage in Patients with Benign Prostatic Hyperplasia and Prostate Cancer Co-Exposed to Phthalates and to Trace Elements. 38
31403918 2019
32
Effects of isocorynoxeine, from Uncaria, on lower urinary tract dysfunction caused by benign prostatic hyperplasia via antagonism of α1A-adrenoceptors. 38
31145917 2019
33
Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms? 38
31392577 2019
34
Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk. 38
31376187 2019
35
Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value. 38
31414754 2019
36
Epidemiology Update of Erectile Dysfunction in Eight Countries with High Burden. 38
31416758 2019
37
A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. 38
31243101 2019
38
Changes in the oxidative stress factors and inflammatory proteins following the treatment of BPH-induced dogs with an anti-proliferative agent called tadalafil. 38
31410874 2019
39
Holter Monitoring (24-Hour ECG) Parameter Dynamics in Patients with Ischemic Heart Disease and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. 38
31148056 2019
40
Serum C-reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia. 38
31165507 2019
41
E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. 38
31212363 2019
42
The independent association of non-alcoholic fatty liver disease with lower urinary tract symptoms/benign prostatic hyperplasia and erectile function scores. 38
30900792 2019
43
α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. 38
30840545 2019
44
Effects of inflammatory responses, apoptosis, and STAT3/NF-κB- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet. 38
31412319 2019
45
Comparison of Diode Laser (980 nm) Enucleation vs Holmium Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial with 12-Month Follow-Up. 38
31298571 2019
46
Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. 38
31433119 2019
47
The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy. 38
31129193 2019
48
Re: Association of Prostatic Volume and Carotid Intima-Media Thickness in Patients with Benign Prostatic Hyperplasia. 38
31021287 2019
49
Re: Convective Radiofrequency Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: A Single Office Experience. 38
31021289 2019
50
Re: Allopurinol and Risk of Benign Prostatic Hyperplasia in a Finnish Population-Based Cohort. 38
31021294 2019

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 KLK3 EGFR EGF AR
2 12.53 KLK3 ESR1 EGFR EGF AR
3
Show member pathways
12.48 PGR ESR1 EGFR EGF
4
Show member pathways
12.04 EGFR ADRA1D ADRA1A
5 11.64 ESR1 EGFR CYP19A1 AR
6 11.61 KLK3 EGFR AR
7
Show member pathways
11.59 PGR ESR1 AR
8 11.43 ESR1 EGFR EGF
9
Show member pathways
11.42 KLK3 EGFR EGF AR
10 11.18 ESR1 EGFR CD36
11 11.1 PGR CYP19A1
12
Show member pathways
11.1 KLK3 ESR1 AR
13 11.08 EGFR EGF
14 10.99 EGFR EGF
15
Show member pathways
10.96 EGFR EGF
16
Show member pathways
10.96 PGR ESR1 EGFR EGF
17 10.93 EGFR EGF
18 10.89 ADRA1D ADRA1A
19 10.64 EGFR EGF
20 9.97 ESR1 CYP19A1

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 EGFR EGF AR ADRA1D
2 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 PGR ESR1 AR
3 positive regulation of protein kinase B signaling GO:0051897 9.77 ESR1 EGFR EGF
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.75 ESR1 CD36 ADRA1A
5 cell-cell signaling GO:0007267 9.71 PGR AR ADRA1D ADRA1A
6 positive regulation of vasoconstriction GO:0045907 9.63 EGFR ADRA1A
7 regulation of cell motility GO:2000145 9.62 EGFR EGF
8 ERBB2 signaling pathway GO:0038128 9.62 EGFR EGF
9 activation of phospholipase C activity GO:0007202 9.61 EGFR ADRA1A
10 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.61 EGFR EGF
11 response to lipid GO:0033993 9.58 EGFR CD36
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.57 ADRA1D ADRA1A
13 uterus development GO:0060065 9.56 ESR1 CYP19A1
14 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.55 EGFR EGF
15 androgen metabolic process GO:0008209 9.54 ESR1 CYP19A1
16 steroid hormone mediated signaling pathway GO:0043401 9.54 PGR ESR1 AR
17 regulation of systemic arterial blood pressure GO:0003073 9.52 KLK3 AR
18 adrenergic receptor signaling pathway GO:0071875 9.51 ADRA1D ADRA1A
19 prostate gland growth GO:0060736 9.48 CYP19A1 AR
20 regulation of toll-like receptor signaling pathway GO:0034121 9.46 ESR1 CD36
21 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR EGF
22 positive regulation of MAPK cascade GO:0043410 9.33 CD36 AR ADRA1A
23 morphogenesis of an epithelial fold GO:0060571 9.32 EGFR AR
24 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.26 PGR AR
25 positive regulation of phosphorylation GO:0042327 9.13 EGFR EGF AR
26 mammary gland alveolus development GO:0060749 8.8 ESR1 EGF AR
27 signal transduction GO:0007165 10.04 PGR ESR1 EGFR EGF AR ADRA1D

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 PGR ESR1 EGFR AR
2 lipid binding GO:0008289 9.67 PGR ESR1 CD36 AR
3 ATPase binding GO:0051117 9.5 PGR ESR1 AR
4 adrenergic receptor activity GO:0004935 9.46 ADRA1D ADRA1A
5 steroid hormone receptor activity GO:0003707 9.43 PGR ESR1 AR
6 nitric-oxide synthase regulator activity GO:0030235 9.4 ESR1 EGFR
7 nuclear receptor activity GO:0004879 9.33 PGR ESR1 AR
8 alpha1-adrenergic receptor activity GO:0004937 8.96 ADRA1D ADRA1A
9 steroid binding GO:0005496 8.8 PGR ESR1 AR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....